Cargando…
Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist
PURPOSE: Glucocorticoids can either suppress gene transcription (transrepression) or activate it (transactivation). This latter process may contribute to certain side effects caused by these agents. Mapracorat (also known as BOL-303242-X or ZK 245186) is a novel selective glucocorticoid receptor ago...
Autores principales: | Baiula, Monica, Spartà, Antonino, Bedini, Andrea, Carbonari, Gioia, Bucolo, Claudio, Ward, Keith W., Zhang, Jin-Zhong, Govoni, Paolo, Spampinato, Santi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Vision
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244483/ https://www.ncbi.nlm.nih.gov/pubmed/22194647 |
Ejemplares similares
-
Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy
por: Baiula, Monica, et al.
Publicado: (2014) -
Therapeutic Targeting of Eosinophil Adhesion and Accumulation in Allergic Conjunctivitis
por: Baiula, Monica, et al.
Publicado: (2012) -
Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells
por: Cavet, Megan E., et al.
Publicado: (2013) -
Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells
por: Cavet, Megan E., et al.
Publicado: (2010) -
Quantitative Systems Pharmacology and Biased Agonism at Opioid Receptors: A Potential Avenue for Improved Analgesics
por: Bedini, Andrea, et al.
Publicado: (2022)